Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x100px

Product › Details

Sandimmun®

	Next higher product group	cyclosporine (INN)
	Status	1993-01-01 sales existent
	Status	1998-01-01 sales existent
	Organisation	Sandoz AG
	Today	Novartis AG (NYSE: NVS)
	Group	Novartis (Group)

Record changed: 2023-07-10

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x200px

More documents for immuno modulatory compound (IMO)

[1] Citryll B.V.. (12/9/24). "Press Release: Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders". Oss....
[2] Immunic, Inc.. (7/24/24). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec". New York, NY....
[3] NXI Therapeutics AG. (6/18/24). "Press Release: NXI Therapeutics Extends Pre-Seed Financing to CHF 3.5 Million in Run-up to Larger Seed Financing". Basel....
[4] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
[5] Odyssey Therapeutics, Inc.. (12/5/23). "Press Release: Odyssey Therapeutics Announces $101 Million Series C Financing". Boston, MA....
[6] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
[7] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
[8] BioNTech SE. (11/30/22). "Press Release: BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates". Mainz & Krakow....
[9] Kupando GmbH. (9/26/22). "Press Release: Kupando Raises €13 Million in Series A Funding Round". Schönefeld....
[10] Tridek-One SAS. (9/15/22). "Press Release: Tridek-One Closes a €16 Million Financing Round to Develop First-in-Class Immune Checkpoint Agonists". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)